Trial Profile

Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venetoclax (Primary) ; Acalabrutinib; Ibrutinib; Zanubrutinib
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use

Most Recent Events

07 Jan 2025 Planned initiation date changed from 1 Jan 2025 to 1 Apr 2025.
04 Nov 2024 Planned End Date changed from 31 Dec 2029 to 31 Dec 2030.
04 Nov 2024 Planned primary completion date changed from 30 Jun 2029 to 30 Jun 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com